Table 1.
Baseline demographic and clinical characteristics of 1236 HIV-positive participants enrolled in Pediatric AIDS Clinical Trials Group protocols 219 and 219C during the period 1 January 1996–30 June 2006.
| Characteristic | No. (%) of patients (n = 1236) |
|---|---|
| Antiretroviral therapya | |
| Non-HAART regimen | 1236 (100) |
| HAART regimen | 0 (0) |
| Age | |
| <5 years | 354 (29) |
| ⩾5 years | 882 (71) |
| Sex | |
| Female | 627 (51) |
| Male | 609 (49) |
| Race or ethnicity | |
| White/Asian/other | 176 (14) |
| Black | 690 (56) |
| Hispanic | 370 (30) |
| Year of study entry | |
| 1996 | 819 (66) |
| 1997 | 155 (13) |
| 1998–2000 | 102 (8) |
| 2001–2006 | 160 (13) |
| Centers for Disease Control and Prevention clinical category | |
| N/A/B | 885 (72) |
| C | 351 (28) |
| CD4+ cell percentage | |
| <15% | 257 (20) |
| 15%–24% | 304 (25) |
| ⩾25% | 675 (55) |
| Total lymphocyte count | |
| <1500 cells/µL | 225 (18) |
| ⩾1500 cells/µL | 1011 (82) |
| WBC count | |
| <3000 cells/µL | 82 (7) |
| ⩾3000 cells/µL | 1154 (93) |
| Hematocrit | |
| <35% | 528 (43) |
| ⩾35% | 708 (57) |
| Albumin level | |
| ⩽4.0 g/dL | 419 (34) |
| >4.0 g/dL | 817 (66) |
a
No children had experienced HAART at baseline, because this was one of the inclusion criteria.